Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 30 of 54 results for durvalumab

  1. Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415

    In development [GID-TA11503] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  2. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development [GID-TA11232] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  3. Treatments for non-small-cell lung cancer [ID6234]

    In development [GID-TA11289] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736

    Awaiting development [GID-TA11076] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]

    Awaiting development [GID-TA11115] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development [GID-NG10404] Expected publication date: TBC

    NICE guideline
    In development

  7. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development [GID-TA11019] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1017)

    Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults

    Technology appraisal guidance
    Published
    20 November 2024
    View recommendations

    Sections for TA1017

  9. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development [GID-TA10911] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer ID6490

    Awaiting development [GID-TA11624] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]

    Awaiting development [GID-TA11670] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]

    Discontinued [GID-TA10394]

    Technology appraisal guidance
    Discontinued

  13. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued [GID-TA10324]

    Technology appraisal guidance
    Discontinued

  14. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued [GID-TA10315]

    Technology appraisal guidance
    Discontinued

  15. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097]

    Awaiting development [GID-TA11011] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development